Monoclonal antibodies (mAbs) Biosimilars Market Report

Monoclonal antibodies (mAbs) Biosimilars Market - Global Professional Analysis and Forecast to 2026

  • POSTDATE：Jan 17, 2020
  • PAGES：176
  • REPORT CODE：GMM438175
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The worldwide Monoclonal antibodies (mAbs) Biosimilars market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 6.1% during the forecast period.

    This report presents the market size and development trends by detailing the Monoclonal antibodies (mAbs) Biosimilars market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Monoclonal antibodies (mAbs) Biosimilars market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Monoclonal antibodies (mAbs) Biosimilars industry and will help you to build a panoramic view of the industrial development.

    Monoclonal antibodies (mAbs) Biosimilars Market, By Type:

    • Erythropoietin (EPO)

    • Human Growth Hormone (HGH)

    • Granulocyte- Colony Stimulating Factor (G-CSF)

    • Monoclonal Antibody (mAb)

    • Insulin

    • Interferon (IFN)

    • Celltrion

    Monoclonal antibodies (mAbs) Biosimilars Market, By Application:

    • Anti-Cancer

    • Anti-Inflammatory/Autoimmune

    Some of the leading players are as follows:

    • Amega Biotech

    • Celltrion

    • Accord Healthcare

    • Biocon

    • Allergan

    • Others

    • Hospira

    • 3SBio

    • AET Biotech

    Geographically, Major regions are analyzed in details are as follows:

    • North America

    • Europe

    • Asia Pacific

    • Latin America

    • Middle East & Africa

  • Table of Contents

    1 Methodology and Scope

    • 1.1 Market Segmentation & Scope

      • 1.1.1 Technology Type

      • 1.1.2 Product

      • 1.1.3 Application

      • 1.1.4 Regional scope

      • 1.1.5 Estimates and forecast timeline

    • 1.2 Research Methodology

    • 1.3 Information Procurement

      • 1.3.1 Purchased database

      • 1.3.2 Internal database

      • 1.3.3 Secondary sources

      • 1.3.4 Primary research

      • 1.3.5 Details of primary research

    • 1.4 Information or Data Analysis

      • 1.4.1 Data analysis models

    • 1.5 Market Formulation & Validation

    • 1.6 Model Details

      • 1.6.1 Commodity flow analysis

      • 1.6.2 Volume price analysis

    • 1.7 List of Secondary Sources

    • 1.8 List of Abbreviations

    2 Executive Summary

    • 2.1 Market Outlook

    • 2.2 Segment Outlook

    3 Market Variables, Trends, & Scope

    • 3.1 Market Lineage Outlook

    • 3.1.1 Parent market outlook

      • 3.1.2 Ancillary market outlook

    • 3.2 Market Segmentation

      • 3.2.1 Analysis

    • 3.3 Market Dynamics

      • 3.3.1 Market driver analysis

      • 3.3.2 Market restraint analysis

      • 3.3.3 Industry opportunities

    • 3.4 Penetration & Growth Prospect Mapping

      • 3.4.1 Penetration & growth prospect mapping analysis

    • 3.5 Business Environment Analysis Tools

      • 3.5.1 Porter's five forces analysis

      • 3.5.2 PESTLE analysis

      • 3.5.3 Major deals & strategic alliances analysis

    4 Monoclonal antibodies (mAbs) Biosimilars Market: Technology Type Analysis

    • 4.1 Monoclonal antibodies (mAbs) Biosimilars Technology Type Market Share Analysis, 2018 & 2026

    • 4.2 Monoclonal antibodies (mAbs) Biosimilars Technology Type Market: Segment Dashboard

    • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

      • 4.3.1 Erythropoietin (EPO)

      • 4.3.2 Human Growth Hormone (HGH)

      • 4.3.3 Granulocyte- Colony Stimulating Factor (G-CSF)

      • 4.3.4 Monoclonal Antibody (mAb)

      • 4.3.5 Insulin

      • 4.3.6 Interferon (IFN)

      • 4.3.7 Celltrion

    5 Monoclonal antibodies (mAbs) Biosimilars Market: Product Analysis

    • 5.1 Monoclonal antibodies (mAbs) Biosimilars Product Market Share Analysis, 2018 & 2026

    • 5.2 Monoclonal antibodies (mAbs) Biosimilars Product Market: Segment Dashboard

    • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

    6 Monoclonal antibodies (mAbs) Biosimilars Market: Application Analysis

    • 6.1 Monoclonal antibodies (mAbs) Biosimilars Application Market Share Analysis, 2018 & 2026

    • 6.2 Monoclonal antibodies (mAbs) Biosimilars Application Market: Segment Dashboard

    • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

      • 6.3.1 Anti-Cancer

      • 6.3.2 Anti-Inflammatory/Autoimmune

    7 Monoclonal antibodies (mAbs) Biosimilars Market: Regional Analysis

    • 7.1 Monoclonal antibodies (mAbs) Biosimilars Regional Market Share Analysis, 2018 & 2026

    • 7.2 Monoclonal antibodies (mAbs) Biosimilars Regional Market: Segment Dashboard

    • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

    • 7.4 List of Players at Regional Level

      • 7.4.1 North America

      • 7.4.2 Europe

      • 7.4.3 Asia Pacific

    • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

      • 7.5.1 North America

      • 7.5.2 Europe

      • 7.5.3 Asia Pacific

      • 7.5.4 Latin America

      • 7.5.5 MEA

    • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

      • 7.6.1 North America

      • 7.6.2 Europe

      • 7.6.3 Asia Pacific

      • 7.6.4 Latin America

      • 7.6.5 Middle East & Africa

    8 Competitive Analysis

    • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

    • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

    • 8.3 Vendor Landscape

      • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

    9 Company Profiles

    • 9.1 Amega Biotech

      • 9.1.1 Amega Biotech Company overview

      • 9.1.2 Financial performance

      • 9.1.3 Product benchmarking

      • 9.1.4 Strategic initiatives

      • 9.1.5 SWOT analysis

    • 9.2 Celltrion

      • 9.2.1 Celltrion Company overview

      • 9.2.2 Financial performance

      • 9.2.3 Product benchmarking

      • 9.2.4 Strategic initiatives

      • 9.2.5 SWOT analysis

    • 9.3 Accord Healthcare

      • 9.3.1 Accord Healthcare Company overview

      • 9.3.2 Financial performance

      • 9.3.3 Product benchmarking

      • 9.3.4 Strategic initiatives

      • 9.3.5 SWOT analysis

    • 9.4 Biocon

      • 9.4.1 Biocon Company overview

      • 9.4.2 Financial performance

      • 9.4.3 Product benchmarking

      • 9.4.4 Strategic initiatives

      • 9.4.5 SWOT analysis

    • 9.5 Allergan

      • 9.5.1 Allergan Company overview

      • 9.5.2 Financial performance

      • 9.5.3 Product benchmarking

      • 9.5.4 Strategic initiatives

      • 9.5.5 SWOT analysis

    • 9.6 Others

      • 9.6.1 Others Company overview

      • 9.6.2 Financial performance

      • 9.6.3 Product benchmarking

      • 9.6.4 Strategic initiatives

      • 9.6.5 SWOT analysis

    • 9.7 Hospira

      • 9.7.1 Hospira Company overview

      • 9.7.2 Financial performance

      • 9.7.3 Product benchmarking

      • 9.7.4 Strategic initiatives

      • 9.7.5 SWOT analysis

    • 9.8 3SBio

      • 9.8.1 3SBio Company overview

      • 9.8.2 Financial performance

      • 9.8.3 Product benchmarking

      • 9.8.4 Strategic initiatives

      • 9.8.5 SWOT analysis

    • 9.9 AET Biotech

      • 9.9.1 AET Biotech Company overview

      • 9.9.2 Financial performance

      • 9.9.3 Product benchmarking

      • 9.9.4 Strategic initiatives

      • 9.9.5 SWOT analysis

     

    The List of Tables and Figures (Totals 71 Figures and 136 Tables)

    • Figure Erythropoietin (EPO) Monoclonal antibodies (mAbs) Biosimilars market, 2015 - 2026 (USD Million)

    • Figure Human Growth Hormone (HGH) Monoclonal antibodies (mAbs) Biosimilars market, 2015 - 2026 (USD Million)

    • Figure Granulocyte- Colony Stimulating Factor (G-CSF) Monoclonal antibodies (mAbs) Biosimilars market, 2015 - 2026 (USD Million)

    • Figure Monoclonal Antibody (mAb) Monoclonal antibodies (mAbs) Biosimilars market, 2015 - 2026 (USD Million)

    • Figure Insulin Monoclonal antibodies (mAbs) Biosimilars market, 2015 - 2026 (USD Million)

    • Figure Interferon (IFN) Monoclonal antibodies (mAbs) Biosimilars market, 2015 - 2026 (USD Million)

    • Figure Celltrion Monoclonal antibodies (mAbs) Biosimilars market, 2015 - 2026 (USD Million)

    • Figure Anti-Cancer market, 2015 - 2026 (USD Million)

    • Figure Anti-Inflammatory/Autoimmune market, 2015 - 2026 (USD Million)

    • Table List of players in North America

    • Table List of players in Europe

    • Table List of players in Asia Pacific

    • Table SWOT analysis

    • Table North America Monoclonal antibodies (mAbs) Biosimilars market, by country, 2015 - 2026 (USD Million)

    • Table North America Monoclonal antibodies (mAbs) Biosimilars market, by type, 2015 - 2026 (USD Million)

    • Table North America Monoclonal antibodies (mAbs) Biosimilars market, by product, 2015 - 2026 (USD Million)

    • Table North America Monoclonal antibodies (mAbs) Biosimilars market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table U.S. Monoclonal antibodies (mAbs) Biosimilars market, by type, 2015 - 2026 (USD Million)

    • Table U.S. Monoclonal antibodies (mAbs) Biosimilars market, by product, 2015 - 2026 (USD Million)

    • Table U.S. Monoclonal antibodies (mAbs) Biosimilars market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Canada Monoclonal antibodies (mAbs) Biosimilars market, by type, 2015 - 2026 (USD Million)

    • Table Canada Monoclonal antibodies (mAbs) Biosimilars market, by product, 2015 - 2026 (USD Million)

    • Table Canada Monoclonal antibodies (mAbs) Biosimilars market, by application, 2015 - 2026 (USD Million)

    • Table Europe Monoclonal antibodies (mAbs) Biosimilars market, by country, 2015 - 2026 (USD Million)

    • Table Europe Monoclonal antibodies (mAbs) Biosimilars market, by type, 2015 - 2026 (USD Million)

    • Table Europe Monoclonal antibodies (mAbs) Biosimilars market, by product, 2015 - 2026 (USD Million)

    • Table Europe Monoclonal antibodies (mAbs) Biosimilars market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table U.K. Monoclonal antibodies (mAbs) Biosimilars market, by type, 2015 - 2026 (USD Million)

    • Table U.K. Monoclonal antibodies (mAbs) Biosimilars market, by product, 2015 - 2026 (USD Million)

    • Table U.K. Monoclonal antibodies (mAbs) Biosimilars market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Germany Monoclonal antibodies (mAbs) Biosimilars market, by type, 2015 - 2026 (USD Million)

    • Table Germany Monoclonal antibodies (mAbs) Biosimilars market, by product, 2015 - 2026 (USD Million)

    • Table Germany Monoclonal antibodies (mAbs) Biosimilars market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table France Monoclonal antibodies (mAbs) Biosimilars market, by type, 2015 - 2026 (USD Million)

    • Table France Monoclonal antibodies (mAbs) Biosimilars market, by product, 2015 - 2026 (USD Million)

    • Table France Monoclonal antibodies (mAbs) Biosimilars market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Italy Monoclonal antibodies (mAbs) Biosimilars market, by type, 2015 - 2026 (USD Million)

    • Table Italy Monoclonal antibodies (mAbs) Biosimilars market, by product, 2015 - 2026 (USD Million)

    • Table Italy Monoclonal antibodies (mAbs) Biosimilars market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Spain Monoclonal antibodies (mAbs) Biosimilars market, by type, 2015 - 2026 (USD Million)

    • Table Spain Monoclonal antibodies (mAbs) Biosimilars market, by product, 2015 - 2026 (USD Million)

    • Table Spain Monoclonal antibodies (mAbs) Biosimilars market, by application, 2015 - 2026 (USD Million)

    • Table Asia Pacific Monoclonal antibodies (mAbs) Biosimilars market, by country, 2015 - 2026 (USD Million)

    • Table Asia Pacific Monoclonal antibodies (mAbs) Biosimilars market, by type, 2015 - 2026 (USD Million)

    • Table Asia Pacific Monoclonal antibodies (mAbs) Biosimilars market, by product, 2015 - 2026 (USD Million)

    • Table Asia Pacific Monoclonal antibodies (mAbs) Biosimilars market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table China Monoclonal antibodies (mAbs) Biosimilars market, by type, 2015 - 2026 (USD Million)

    • Table China Monoclonal antibodies (mAbs) Biosimilars market, by product, 2015 - 2026 (USD Million)

    • Table China Monoclonal antibodies (mAbs) Biosimilars market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Japan Monoclonal antibodies (mAbs) Biosimilars market, by type, 2015 - 2026 (USD Million)

    • Table Japan Monoclonal antibodies (mAbs) Biosimilars market, by product, 2015 - 2026 (USD Million)

    • Table Japan Monoclonal antibodies (mAbs) Biosimilars market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table India Monoclonal antibodies (mAbs) Biosimilars market, by type, 2015 - 2026 (USD Million)

    • Table India Monoclonal antibodies (mAbs) Biosimilars market, by product, 2015 - 2026 (USD Million)

    • Table India Monoclonal antibodies (mAbs) Biosimilars market, by application, 2015 - 2026 (USD Million)

    • Table Latin America Monoclonal antibodies (mAbs) Biosimilars market, by country, 2015 - 2026 (USD Million)

    • Table Latin America Monoclonal antibodies (mAbs) Biosimilars market, by type, 2015 - 2026 (USD Million)

    • Table Latin America Monoclonal antibodies (mAbs) Biosimilars market, by product, 2015 - 2026 (USD Million)

    • Table Latin America Monoclonal antibodies (mAbs) Biosimilars market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Brazil Monoclonal antibodies (mAbs) Biosimilars market, by type, 2015 - 2026 (USD Million)

    • Table Brazil Monoclonal antibodies (mAbs) Biosimilars market, by product, 2015 - 2026 (USD Million)

    • Table Brazil Monoclonal antibodies (mAbs) Biosimilars market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Mexico Monoclonal antibodies (mAbs) Biosimilars market, by type, 2015 - 2026 (USD Million)

    • Table Mexico Monoclonal antibodies (mAbs) Biosimilars market, by product, 2015 - 2026 (USD Million)

    • Table Mexico Monoclonal antibodies (mAbs) Biosimilars market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Argentina Monoclonal antibodies (mAbs) Biosimilars market, by type, 2015 - 2026 (USD Million)

    • Table Argentina Monoclonal antibodies (mAbs) Biosimilars market, by product, 2015 - 2026 (USD Million)

    • Table Argentina Monoclonal antibodies (mAbs) Biosimilars market, by application, 2015 - 2026 (USD Million)

    • Table MEA Monoclonal antibodies (mAbs) Biosimilars market, by country, 2015 - 2026 (USD Million)

    • Table MEA Monoclonal antibodies (mAbs) Biosimilars market, by type, 2015 - 2026 (USD Million)

    • Table MEA Monoclonal antibodies (mAbs) Biosimilars market, by product, 2015 - 2026 (USD Million)

    • Table MEA Monoclonal antibodies (mAbs) Biosimilars market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table South Africa Monoclonal antibodies (mAbs) Biosimilars market, by type, 2015 - 2026 (USD Million)

    • Table South Africa Monoclonal antibodies (mAbs) Biosimilars market, by product, 2015 - 2026 (USD Million)

    • Table South Africa Monoclonal antibodies (mAbs) Biosimilars market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Nigeria Monoclonal antibodies (mAbs) Biosimilars market, by type, 2015 - 2026 (USD Million)

    • Table Nigeria Monoclonal antibodies (mAbs) Biosimilars market, by product, 2015 - 2026 (USD Million)

    • Table Nigeria Monoclonal antibodies (mAbs) Biosimilars market, by application, 2015 - 2026 (USD Million)

    • Table Recent Developments & Impact Analysis, by Key Market Participants

    • Table Recent Developments & Impact Analysis, by Key Market Participants

    • Table Company market position analysis

    • Table Company Profiles

    • Table Amega Biotech Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Celltrion Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Accord Healthcare Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Biocon Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Allergan Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Others Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Hospira Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table 3SBio Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table AET Biotech Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US